BR112022004994A2 - Preparação contendo albumina humana e seu método de preparação - Google Patents
Preparação contendo albumina humana e seu método de preparaçãoInfo
- Publication number
- BR112022004994A2 BR112022004994A2 BR112022004994A BR112022004994A BR112022004994A2 BR 112022004994 A2 BR112022004994 A2 BR 112022004994A2 BR 112022004994 A BR112022004994 A BR 112022004994A BR 112022004994 A BR112022004994 A BR 112022004994A BR 112022004994 A2 BR112022004994 A2 BR 112022004994A2
- Authority
- BR
- Brazil
- Prior art keywords
- acid
- preparation
- human albumin
- chain fatty
- long
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
preparação contendo albumina humana e seu método de preparação. a presente invenção refere-se a um método para a preparação de uma preparação de albumina humana, o método compreendendo controlar o teor de um ácido graxo de cadeia longa na preparação; e adicionar um poloxâmero. o ácido graxo de cadeia longa é selecionado a partir de um ou mais de ácido mirístico, ácido palmítico, ácido esteárico, ácido oleico, ácido linoleico, ácido linolênico e ácido araquidônico, e a razão molar dos ácidos graxos de cadeia longa ácido para albumina humana é de 0,2 a 3,0. o teor do poloxâmero é de 10 a 500 microgramas por grama de albumina humana. a preparação de albumina humana preparada por meio do método tem uma estabilidade aprimorada e está livre de uma partícula com um tamanho de partícula de pelo menos 30 nm formado por agregação e/ou fibrilação de albumina humana.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910874343.3A CN112516291B (zh) | 2019-09-17 | 2019-09-17 | 含人白蛋白的制剂及其制备方法 |
| PCT/CN2020/086057 WO2021051807A1 (zh) | 2019-09-17 | 2020-04-22 | 含人白蛋白的制剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022004994A2 true BR112022004994A2 (pt) | 2022-06-21 |
Family
ID=74883661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022004994A BR112022004994A2 (pt) | 2019-09-17 | 2020-04-22 | Preparação contendo albumina humana e seu método de preparação |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220313790A1 (pt) |
| EP (1) | EP4032541A4 (pt) |
| JP (1) | JP7414326B2 (pt) |
| KR (1) | KR20220061964A (pt) |
| CN (1) | CN112516291B (pt) |
| BR (1) | BR112022004994A2 (pt) |
| CA (1) | CA3154018A1 (pt) |
| WO (1) | WO2021051807A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114544926A (zh) * | 2021-12-02 | 2022-05-27 | 浙江鑫科医疗科技有限公司 | 一种血清蛋白稳定剂 |
| CN115677848A (zh) * | 2022-10-24 | 2023-02-03 | 通化安睿特生物制药股份有限公司 | 一种制备高纯度高稳定性蛋白质的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004075913A1 (ja) * | 2003-02-28 | 2004-09-10 | Chugai Seiyaku Kabushiki Kaisha | タンパク質含有安定化製剤 |
| CN1919339B (zh) * | 2006-06-13 | 2013-01-23 | 沈阳药科大学 | 含有蛋白的葫芦素纳米制剂及制备方法和用途 |
| CN101745103B (zh) * | 2010-01-19 | 2011-09-28 | 广东卫伦生物制药有限公司 | 可常温保存的白蛋白制剂 |
| AU2013230020B2 (en) | 2012-03-07 | 2018-08-09 | Janssen Biotech, Inc. | Defined media for expansion and maintenance of pluripotent stem cells |
| US20150165000A1 (en) * | 2012-12-18 | 2015-06-18 | Ewha University - Industry Collaboration Foundation | Composition for thermostabilization of human serum albumin and method of preparing thermally stabilized human serum albumin using the same |
| WO2018115953A1 (en) | 2016-12-21 | 2018-06-28 | Prometic Pharma Smt Limited | Methods and compositions for preventing or minimizing epithelial-mesenchymal transition |
| CN107674860A (zh) * | 2017-07-14 | 2018-02-09 | 上海源培生物科技股份有限公司 | Nk92细胞无血清培养基 |
-
2019
- 2019-09-17 CN CN201910874343.3A patent/CN112516291B/zh active Active
-
2020
- 2020-04-22 US US17/642,239 patent/US20220313790A1/en active Pending
- 2020-04-22 CA CA3154018A patent/CA3154018A1/en active Pending
- 2020-04-22 JP JP2022510834A patent/JP7414326B2/ja active Active
- 2020-04-22 KR KR1020227007537A patent/KR20220061964A/ko unknown
- 2020-04-22 BR BR112022004994A patent/BR112022004994A2/pt unknown
- 2020-04-22 EP EP20866272.6A patent/EP4032541A4/en active Pending
- 2020-04-22 WO PCT/CN2020/086057 patent/WO2021051807A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4032541A4 (en) | 2022-11-23 |
| EP4032541A1 (en) | 2022-07-27 |
| US20220313790A1 (en) | 2022-10-06 |
| CN112516291B (zh) | 2023-07-14 |
| KR20220061964A (ko) | 2022-05-13 |
| JP7414326B2 (ja) | 2024-01-16 |
| WO2021051807A1 (zh) | 2021-03-25 |
| CA3154018A1 (en) | 2021-03-25 |
| JP2022545214A (ja) | 2022-10-26 |
| CN112516291A (zh) | 2021-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022004994A2 (pt) | Preparação contendo albumina humana e seu método de preparação | |
| Soleimanian et al. | Formulation and characterization of novel nanostructured lipid carriers made from beeswax, propolis wax and pomegranate seed oil | |
| Yang et al. | The effect of oil type on the aggregation stability of nanostructured lipid carriers | |
| HRP20161272T4 (hr) | Učinci metaboličkog utiskivanja specifično dizajnirane lipidne komponente | |
| RU2011128449A (ru) | Композиции для питания с покрытыми липидными глобулами | |
| BR112012026223A2 (pt) | formulação adequada para o uso em ração animal, uso, e ração para animais. | |
| CN102215839B (zh) | 用于人工喂养重病的重症特护患者的脂肪乳剂 | |
| EP2720701A1 (en) | Therapeutic application of parenteral krill oil | |
| BR112019005016A2 (pt) | composição para aplicação tópica com atividade antifúngica | |
| JP2020524482A5 (pt) | ||
| Swell et al. | Tissue cholesterol ester and triglyceride fatty acid composition of rabbits fed cholesterol diets high and low in linoleic acid | |
| WO2022073439A1 (zh) | 一种纳米硒皮克林乳液及其制备方法与应用 | |
| MX2021014561A (es) | Uso de una composicion de albumina con o sin agentes pro-emt y anti-emt (agentes para prevenir o minimizar la transicion epitelio mesenquima emt), para el tratamiento de enfermedades o afecciones de hemorragias, quemaduras, disfuncion hepatica, cancer, etc. | |
| JP2015510760A5 (pt) | ||
| JP2014185107A (ja) | 経口組成物 | |
| EP2120596A1 (en) | A product based on conjugated linoleic acid and a method for the manufacture thereof | |
| JP2015506175A (ja) | Ｄｈａおよびｅｐａを含む有機エマルション | |
| KR960700040A (ko) | 활성물질을 함유하는 동결건조 유제(Lyophilized emulsion containing an active substance) | |
| CA2455226A1 (en) | Compositions comprising an o/w emulsion containing conjugated linoleic acid | |
| Donaldson | Lipid composition of chick embryo and yolk as affected by stage of incubation and maternal diet | |
| Hafandi et al. | Dietary Repletion with ω3 Fatty Acid or with COX Inhibition Reverses Cognitive Effects in F3 ω3 Fatty-Acid–Deficient Mice | |
| BR0318602A (pt) | óleo de girassol, planta de girassol, sementes de girassol, método para produção de uma planta que forma sementes contendo um óleo endógeno, planta hìbrida, progenitura de planta hìbrida, óleo, e produto alimentìcio | |
| BR112018074014A2 (pt) | composição de lipídios em pó que compreende uma mistura de sal | |
| BR112019018105A2 (pt) | Composição de emulsão ácida | |
| BR102019028159A2 (pt) | micropartículas de pectina cítrica contendo sulfato ferroso e processo de obtenção |